{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:18:33Z","timestamp":1787843913405,"version":"build-2784847793"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-026-04245-x","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:30:36Z","timestamp":1787841036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dexamethasone intravitreal implant (Ozurdex) monotherapy for uveitic macular edema secondary to non-infectious uveitis: a single-center retrospective cohort study"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5810-1967","authenticated-orcid":false,"given":"Ermal","family":"Simaku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megi","family":"Popa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"4245_CR1","doi-asserted-by":"publisher","first-page":"CD010469","DOI":"10.1002\/14651858.CD010469.pub4","volume":"8","author":"A Reddy","year":"2023","unstructured":"Reddy A, Liu SH, Brady CJ, Sieving PC, Palestine AG (2023) Corticosteroid implants for chronic non-infectious uveitis. Cochrane Database Syst Rev 8:CD010469. https:\/\/doi.org\/10.1002\/14651858.CD010469.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"4245_CR2","doi-asserted-by":"publisher","unstructured":"Yap YC, Papathomas T, Kamal A (2015) Results of intravitreal dexamethasone implant 0.7\u00a0mg (Ozurdex\u00ae) in non-infectious posterior uveitis. Int J Ophthalmol https:\/\/doi.org\/10.3980\/j.issn.2222-3959.2015.04.34.","DOI":"10.3980\/j.issn.2222-3959.2015.04.34"},{"key":"4245_CR3","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S17419","author":"RS Hunter","year":"2011","unstructured":"Hunter RS, Lobo AM (2011) Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clin Ophthalmol. https:\/\/doi.org\/10.2147\/OPTH.S17419","journal-title":"Clin Ophthalmol"},{"key":"4245_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.339","author":"C Lowder","year":"2011","unstructured":"Lowder C, Belfort R Jr, Lightman S et al (2011) Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. https:\/\/doi.org\/10.1001\/archophthalmol.2010.339","journal-title":"Arch Ophthalmol"},{"key":"4245_CR5","doi-asserted-by":"publisher","unstructured":"Thorne JE, Sugar EA, Holbrook JT et al, Multicenter Uveitis Steroid Treatment Trial Research Group (2019) Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the POINT Trial. Ophthalmology. 126(2):283\u2013295. https:\/\/doi.org\/10.1016\/j.ophtha.2018.08.021.","DOI":"10.1016\/j.ophtha.2018.08.021"},{"key":"4245_CR6","doi-asserted-by":"publisher","unstructured":"Multicenter Uveitis Steroid Treatment Trial Research Group, Writing Committee; Acharya NR, Vitale AT, Sugar EA et al (2023) Intravitreal therapy for uveitic macular edema-ranibizumab versus methotrexate versus the dexamethasone implant: the MERIT Trial results. Ophthalmology 130(9):914\u2013923. https:\/\/doi.org\/10.1016\/j.ophtha.2023.04.011.","DOI":"10.1016\/j.ophtha.2023.04.011"},{"key":"4245_CR7","doi-asserted-by":"publisher","first-page":"1126724","DOI":"10.3389\/fmed.2023.1126724","volume":"10","author":"S Fan","year":"2023","unstructured":"Fan S, Shi XY, Zhao CF et al (2023) Efficacy and safety of single-dose intravitreal dexamethasone implant in non-infectious uveitic macular edema: a systematic review and meta-analysis. Front Med (Lausanne) 10:1126724. https:\/\/doi.org\/10.3389\/fmed.2023.1126724","journal-title":"Front Med (Lausanne)"},{"key":"4245_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12348-023-00360-3","volume":"13","author":"RB Gupta","year":"2023","unstructured":"Gupta RB, Ilin J, Gottlieb CC (2023) Efficacy of intravitreal dexamethasone implant used as monotherapy for the treatment of macular edema in non-infectious uveitis: a retrospective analysis. J Ophthalmic Inflamm Infect 13:42. https:\/\/doi.org\/10.1186\/s12348-023-00360-3","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"4245_CR9","doi-asserted-by":"publisher","unstructured":"Zeng S, Liu XL (2023) A review of ten years of experience using dexamethasone intravitreal implants (Ozurdex) for uveitis. Eur Rev Med Pharmacol Sci 27(5):1743\u20131758. https:\/\/doi.org\/10.26355\/eurrev_202303_31535.","DOI":"10.26355\/eurrev_202303_31535"},{"key":"4245_CR10","doi-asserted-by":"publisher","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature Working Group (2005) Standardization of uveitis nomenclature for reporting clinical data: results of the first international workshop. Am J Ophthalmol https:\/\/doi.org\/10.1016\/j.ajo.2005.03.057.","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"4245_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.09.003","author":"J Zarranz-Ventura","year":"2014","unstructured":"Zarranz-Ventura J, Carre\u00f1o E, Johnston RL et al (2014) Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol. https:\/\/doi.org\/10.1016\/j.ajo.2014.09.003","journal-title":"Am J Ophthalmol"},{"key":"4245_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.02.003","author":"O Tomkins-Netzer","year":"2014","unstructured":"Tomkins-Netzer O, Taylor SRJ, Bar A et al (2014) Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis. Ophthalmology. https:\/\/doi.org\/10.1016\/j.ophtha.2014.02.003","journal-title":"Ophthalmology"},{"key":"4245_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002901","author":"T Mathis","year":"2021","unstructured":"Mathis T, Cerquaglia A, Weber M et al (2021) Uveitis treated with dexamethasone implant. Retina. https:\/\/doi.org\/10.1097\/IAE.0000000000002901","journal-title":"Retina"},{"key":"4245_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.04.012","author":"JH Cao","year":"2014","unstructured":"Cao JH, Mulvahill M, Zhang L, Joondeph BC, Dacey MS (2014) Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation. Ophthalmology. https:\/\/doi.org\/10.1016\/j.ophtha.2014.04.012","journal-title":"Ophthalmology"},{"key":"4245_CR15","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-10981","author":"S Lightman","year":"2013","unstructured":"Lightman S, Belfort R Jr, Naik RK et al (2013) Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis. Invest Ophthalmol Vis Sci. https:\/\/doi.org\/10.1167\/iovs.12-10981","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4245_CR16","doi-asserted-by":"publisher","DOI":"10.1159\/000343060","author":"E Miserocchi","year":"2012","unstructured":"Miserocchi E, Modorati G, Pastore MR, Bandello F (2012) Dexamethasone intravitreal implant: an effective adjunctive treatment for recalcitrant noninfectious uveitis. Ophthalmologica. https:\/\/doi.org\/10.1159\/000343060","journal-title":"Ophthalmologica"},{"key":"4245_CR17","doi-asserted-by":"publisher","unstructured":"Jaffe GJ, Pavesio CE (2020) Study investigators. Effect of a fluocinolone acetonide insert on recurrence rates in noninfectious intermediate, posterior, or panuveitis: three-year results. Ophthalmology 127(10):1395\u20131404. https:\/\/doi.org\/10.1016\/j.ophtha.2020.04.001.","DOI":"10.1016\/j.ophtha.2020.04.001"},{"issue":"4","key":"4245_CR18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ophtha.2018.10.033","volume":"126","author":"GJ Jaffe","year":"2019","unstructured":"Jaffe GJ, Foster CS, Pavesio CE, Paggiarino DA, Riedel GE (2019) Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve-month results. Ophthalmology 126(4):601\u2013610. https:\/\/doi.org\/10.1016\/j.ophtha.2018.10.033","journal-title":"Ophthalmology"},{"issue":"1","key":"4245_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40123-021-00426-2","volume":"11","author":"M Battista","year":"2022","unstructured":"Battista M, Starace V, Cicinelli MV et al (2022) Efficacy of 0.19 mg fluocinolone acetonide implant in non-infectious posterior uveitis evaluated as area under the curve. Ophthalmol Ther 11(1):215\u2013224. https:\/\/doi.org\/10.1007\/s40123-021-00426-2","journal-title":"Ophthalmol Ther"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04245-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-04245-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04245-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:30:39Z","timestamp":1787841039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-026-04245-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4245"],"URL":"https:\/\/doi.org\/10.1007\/s10792-026-04245-x","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"30 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Council of the University of Medicine, Tirana, Albania (Decision No. 11, dated 18 March 2024), and was conducted in accordance with the Declaration of Helsinki. Patient data were reviewed retrospectively and anonymized before analysis.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"350"}}